Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.
Youngran ParkMichael Herman ChuiYohan Suryo RahmantoZheng-Cheng YuRaghavendra A ShamannaMarina A BellaniStephanie GaillardAyse AyhanAkila ViswanathanMichael M SeidmanSonia FrancoAnthony K L LeungVilhelm A BohrIe-Ming ShihTian-Li WangPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
ARID1A-deficient cells acquire high sensitivity to PARP inhibition after exposure to exogenously induced DNA breaks such as ionizing radiation. Our findings suggest a novel biologically informed strategy for treating ARID1A-deficient malignancies.